Objective To investigate the relationship of serum levels of neuron-specific enolase (NSE), amyloid protein A (AA), interleukin-6 (IL-6) with neurological damage and prognosis in those patients with atherosclerotic stroke. Methods 105 cases of patients with atherosclerosis stroke, ever treated in our hospital from May 2014 to June 2016, were enrolled as the study objectives. The patients with increased levels of NSE, AA and IL-6 were divided into the study group (n=66), while those with normal levels were divided into the control group (n=39). At the day of hospital admission, all patients were evaluated with National Institutes of Health Stroke Scale (NIHSS) score, and their serum levels of NSE, AA and IL-6 were examined. At the 7th and 14th day after admission, they were detected again. The recovery of neurological function was assessed with modified Rankin Scale (mRS) score at 30 days after disease onset or hospital admission. Results At the 1st, 7th and 14th day, the NIHSS scores and serum levels of NSE, AA and IL-6 in the study group were significantly higher than those in the control group (all P<0.05). Compared with the control group, the mRS scores at the 30th day in the study group were 1~2 of 21 cases, 3~4 of 26 cases, and 5~6 of 19 cases, respectively, with significant differences between the two groups (all P<0.05). Conclusion Early detection of serum NSE, AA and IL-6 levels in those patients with atherosclerotic stroke could be used as an indicator of identifying them with poor prognosis earlier. |